Volume 10, Number 5—May 2004
Research
Multidrug-resistant Strains of Salmonella enterica Typhimurium, United States, 1997–19981
Table 1
R-typea | All isolates N (%) | DT104 N (%) | RDNC† N (%) | Untypeable N (%) |
---|---|---|---|---|
ACSSuT |
187 (27) |
160 (62) |
6 (3) |
6 (6) |
ACSSuT+Cl |
11 (1) |
10 (4) |
0 |
0 |
ACSSuT+G |
2 (<1) |
2 (<1) |
0 |
0 |
ACSSuT+N |
4 (<1) |
4 (2) |
0 |
0 |
ACSSuT+Tm |
1 (<1) |
0 |
0 |
0 |
ACSSuT+Cl+Cep |
2 (<1) |
1 (<1) |
0 |
0 |
ACSSuT+Cl+Tm |
1 (<1) |
1 (<1) |
0 |
0 |
ACSSuT+Cl+Cef+Cx+Cep |
1 (<1) |
1 (<1) |
0 |
0 |
ACSSuT total |
209 (30) |
179 (69) |
6 (3) |
6 (6) |
ACKSSuT |
16 (2) |
13 (5) |
1 (<1) |
2 (2) |
ACKSSuT+Cep+Tm |
4 (<1) |
0 |
0 |
4 (4) |
ACKSSuT+Cl+Cef+Cx+Cep |
3 (<1) |
0 |
0 |
3 (3) |
ACKSSuT+Cl+Cef+Cx+Cep+G |
2 (<1) |
1 (<1) |
0 |
1 (1) |
ACKSSuT+Cl+Cef+Cx+Cep+G+Tm |
1 (<1) |
0 |
0 |
1 (1) |
ACKSSuT total |
26 (4) |
14 (5) |
1 (<1) |
11 (11) |
AKSSuT |
51 (7) |
5 (2) |
8 (4) |
34 (33) |
AKSSuT+Cep |
4 (<1) |
1 (<1) |
1 (<1) |
2 (2) |
AKSSuT+G |
1 (<1) |
0 |
1 (<1) |
0 |
AKSSuT+Cl+Cep |
1 (<1) |
0 |
0 |
0 |
AKSSuT+Cep+G |
2 (<1) |
2 (<1) |
0 |
0 |
AKSSuT+Cl+Cep+G |
1 (<1) |
1 (<1) |
0 |
0 |
AKSSuT+Cef+Cx+Cep+N |
1 (<1) |
0 |
0 |
1 (1) |
AKSSuT total |
61 (9) |
9 (4) |
10 (5) |
37 (36) |
Pansusceptible |
295 (42) |
33 (13) |
144 (69) |
26 (25) |
Resistant to 1 antimicrobial agent |
23 (3) |
5 (2) |
11 (5) |
3 (3) |
Resistant to 2 antimicrobial agents |
19 (3) |
7 (3) |
8 (4) |
1 (1) |
Resistant to 3 antimicrobial agents |
21 (3) |
4 (2) |
10 (5) |
4 (4) |
Resistant to 4 antimicrobial agents |
27 (4) |
5 (2) |
11 (5) |
10 (10) |
Resistant to 5 antimicrobial agents |
6 (<1) |
3 (1) |
2 (1) |
1 (1) |
Resistant to 6 antimicrobial agents |
4 (<1) |
0 |
1 (<1) |
0 |
Resistant to 7 antimicrobial agents |
5 (<1) |
0 |
2 (1) |
1 (1) |
Resistant to 9 antimicrobial agents |
1 (<1) |
0 |
0 |
1 (1) |
Total | 697 (100) | 259 (100) | 209 (100) | 104 (100) |
aNARMS, National Antimicrobial Resistance Monitoring System; Cl, amoxicillin-clavulanic acidl; A, ampicillin; Ceft, ceftiofur; Cx, ceftriaxone; Cep, cephalothin; C, chloramphenicol; G, .gentamicin; K, kanamycin; N, nalidixic acid; S, streptomycin; Su, sulfamethoxazole; T, tetracycline; Tm, trimethoprim-sulfamethoxazole.
bReacts but does not conform.
1Presented in part at the International Conference on Emerging Infectious Diseases, July 2000, Atlanta, Georgia, USA.
Page created: February 18, 2011
Page updated: February 18, 2011
Page reviewed: February 18, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.